Disclosure for risk of Alzheimer's disease: development of a manual toward shared decision making

2023 Fiscal Year Final Research Report

• Project/Area Number: 19K03292
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 10030:Clinical psychology-related
• Research Institution: Keio University (2022-2023); Saitama Medical University (2019-2021)
• Principal Investigator: Wake Taisei 慶應義塾大学, 医学部(信濃町), 共同研究員 (80815845)
• Project Period (FY): 2019-04-01 – 2024-03-31
• Keywords: アルツハイマー病 / 発症前診断 / 告知 / アミロイドPET / 生命倫理 / 意思決定支援

Outline of Final Research Achievements

We conducted questionnaires and semi-structured telephone interviews with the subjects to investigate the impact of disclosure. At the same time, a literature review and analysis was conducted about medical actionability. In addition, we reviewed previous research on the disclosure of biomarker tests, including genetic tests regarding the risk of developing Alzheimer's disease. Based on these, a protocol was developed that included a sufficient explanation of the risk of developing Alzheimer's disease evaluated by amyloid PET.

Free Research Field

臨床心理学

Academic Significance and Societal Importance of the Research Achievements

いまだ完全な治療法のないアルツハイマー病の発症リスクが予測可能になりつつある今、発症前診断の安全かつ効果的な告知方法を早急に確立しなければならない。本研究では、発症前診断を安全かつ効果的に告知するためのマニュアルを開発した。これにより、真実を知り自己決定する権利と尊厳を重んじた共同意思決定に基づく新たな認知症医療の先駆けの一つとなった。